You're signed outSign in or to get full access.
Zachary Day most recently served as an Equity Research Analyst at Canaccord Genuity, specializing in healthcare and medical technology, where he covered companies such as TransMedics Group Inc. and AtriCure Inc., participating in earnings calls and industry research. During his tenure, Day demonstrated strong analytical acumen by asking targeted questions to company management, though specific quantitative performance metrics are not published. He began his finance career prior to Canaccord Genuity, later transitioning in 2024 to Excellere Partners, reflecting his progression from research analysis into private equity. Day’s credentials encompass experience in equity research and data analysis, and he has worked with other firms previously, building a foundation for capital markets and transaction diligence, though records of FINRA or licensing details are not publicly available.
Zachary asked for more details on NOP Connect 2.0 and the operational efficiencies observed early on since its implementation.
President and CEO Waleed Hassanein reported that the vast majority of cases now use NOP Connect 2.0, showing efficiencies in management and billing. He expressed encouragement and commitment to continued strategic investments in the digital platform.
Fintool can predict 
TMDX's earnings beat/miss a week before the call
Zachary asked for more details on NOP Connect 2.0, specifically what early operational efficiencies have been observed since its implementation.
Waleed Hassanein, President and CEO, reported that the vast majority of cases now use NOP Connect 2.0, showing efficiency in management and billing. He expects continuous improvement and strategic investments in the digital platform.
Fintool can write a report on TMDX's next earnings in your company's style and formatting
Zachary Day, on for Bill Plozniak, inquired about Q2 market share trends by organ or donation type and the company's perspective on potential new competition in the liver market.
CEO Waleed Hassanein reiterated that the company does not provide intra-year share data but confirmed share gains continued in heart and liver. He stated he was unaware of specific new liver competitors but welcomes competition that aims to save more lives.
Fintool can auto-update your Excel models when TMDX reports
Zachary Day asked for an update on the G7 non-intensive Type 2 covered lives, specifically the progress towards the 25 million goal from the current 6 million, the 12 million from Medicare, and the expected cadence of covered lives expansion.
Jereme Sylvain, Chief Financial Officer, clarified that Medicare coverage would progress from Part B to Part C. On the commercial side, he reported that Dexcom has secured coverage for approximately 6.5 million lives (up from 6 million) out of a 12.5 million commercial target, through major PBMs and an additional 5% from renewals, with ongoing efforts to expand coverage further.
Fintool can predict 
DXCM's earnings beat/miss a week before the call
Zachary Day of Canaccord Genuity asked for an update on G7 non-intensive Type 2 covered lives, specifically the progress from 6 million to 25 million, the 12 million Medicare opportunity, current status, and the expected cadence of covered lives expansion.
Jereme Sylvain, CFO of Dexcom, updated that on the commercial side, Dexcom has secured coverage for an additional 5% of the market through renewals, bringing the total to approximately 6.5 million of the 12.5 million target. He noted that Medicare coverage would start with fee-for-service (Part B) and then move to Medicare Advantage (Part C), with continuous efforts to chip away at expanding commercial coverage beyond annual renewals.
Fintool can write a report on DXCM's next earnings in your company's style and formatting
Zachary Day of Canaccord Genuity inquired about the impact of the LEAPS trial's enrollment completion on AtriClip utilization and how AtriCure manages discussions with electrophysiologists regarding PFA failures.
Michael Carrel, President, Director & CEO, clarified that the conclusion of LEAPS enrollment has a "zero impact" on revenue, as overall AtriClip adoption is rising due to increased market awareness. He described conversations with EPs about PFA as collaborative and scientific, positioning AtriCure's epicardial ablation as an additive therapy for complex patients rather than a direct competitor.
Fintool can predict 
ATRC's earnings beat/miss a week before the call
